Skip to main content

Table 2 Characteristics of the second patient cohort

From: Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis

Characteristic

Second patient cohort (n = 60)

Pretreatment (n = 30)

Posttreatment (n = 30)

Age, years

56 (37–64)

 

Female, n (%)

26 (88)

 

Disease duration, months

13 (3–47)

 

Stage I/II/III/IV, n

14/14/0/2

 

Class 1/2/3/4, n

9/19/2/0

 

RF-positive, n (%)

22 (73)

 

ACPA-positive, n (%)

22 (73)

 

Methotrexate use, n (%)

18 (60)

28 (93)

Biologic use, n (%)

5 (17)

21 (70)

DAS28-ESR

4.8 (3.7–6.4)

2.0 (1.0–2.8)

DAS28-CRP

4.0 (3.2–5.5)

1.5 (1.1–2.3)

SDAI

16.0 (11.5–32.9)

1.8 (0.3–5.4)

CDAI

15.4 (10.8–31.2)

1.8 (0.3–5.4)

SJC, 28 joints, n

4 (3–8.5)

0 (0–1)

TJC, 28 joints, n

6 (3–10)

0 (0–1)

PtGA, mm

48 (27–73)

35 (11–53)

PGA, mm

31 (20–52)

2 (0–11)

CRP, mg/dl

0.5 (0.1–1.2)

0.0 (0.0–0.1)

ESR, mm/h

47 (28–67)

8 (3–24)

MMP-3, ng/ml

79 (49–107)

39 (24–53)

HAQ-DI

0.9 (0.3–1.4)

0.1 (0–0.4)

  1. ACPA anticitrullinated protein antibodies, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count, PtGA patient global assessment, PGA Physician Global Assessment, HAQ-DI Health Assessment Questionnaire Disability Index
  2. Values are median (interquartile range) unless otherwise noted